Experts: Negotiating Big Pharma’s Prices Won’t Stifle Innovation—They Don’t Use the Money to Innovate!
Physician-scientist Fred Ledley and economist William Lazonick debunk Big Pharma arguments against Medicare drug price negotiation
Read more...Physician-scientist Fred Ledley and economist William Lazonick debunk Big Pharma arguments against Medicare drug price negotiation
Read more...The scientific, health, and political debate over the true cost of ultra–processed has just gone mainstream….which is late.
Read more...Tax havens not only facilitate tax evasion and corruption in ‘normal times’, they also harbour funds during economic crises, slowing down recovery.
Read more...How some key points on negotiating Medicare drug prices under the Inflation Reduction Act were oddly left open, arguably much too open.
Read more...How war spending serves as a cover for the distribution of pork at the expense of American needs.
Read more...Because these price spikes are a state of mind. And when that state of mind changes – see Tesla.
Read more...How the education part of higher education has become an afterthought.
Read more...The coming horror of the loss of privacy and degradation of service via the brave new world of AI administered medicine.
Read more...A revealing, and not at all in a good way, discussion of private equity by departing CalSTRS Chief Investment Officer Chris Ailman.
Read more...The formidable and controversial former lawyer Bill Lerach explained in a recent interview why corporate misconduct is so deeply entrenched.
Read more...More on why Medicare Advantage is a criminogenic environment. And private equity has gotten in on the action.
Read more...The alternatives if Biden does not make it to the convention, the options are ugly.
Read more...California’s new rule mandates Covid infection, violates California’s Adminstrative Procedures Act, and its stated purpose is not justified by statute.
Read more...Investor-State Dispute Settlement (ISDS) provisions in trade pacts – long abused by opportunists – are slowly being rejected by governments.
Read more...The FTC is scoring some early wins in challenging drug company overreach via using patents on delivery methods to extend drug patent life.
Read more...